Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
10.5 mg budesonide effervescent tablet for orodispersible use[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
21 mg budesonide effervescent tablet for orodispersible use[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
31mg budesonide effervescent tablet for orodispersible use[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
42mg budesonide effervescent tablet for orodispersible use[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
55 mg Montelukast[1] Montelukast[2] D00529 ,
D08229 		[1] CYSLTR1 💬[2] Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬[1] 98
6AK002----[1] 98
7Allergen----[1] 98
8Allergy immunotherapy (allergy shots)----[1] 98
9APD334----[5] 93, 96, 97, 98, 269
10APT-1011----[1] 98
11APT-1011 - 3 mg----[1] 98
12AR401959 L-arginine[1] Arginine[1] D02982 --[3] 96, 97, 98
13Arginine[1] Arginine[1] D02982 --[11] 46, 58, 67, 78, 96, 97, 98, 113, 210, 251, 299
14Barium[1] Barium---[3] 2, 19, 98
15Beclomethasone dipropionate[1] Beclomethasone dipropionate[2] D00689 ,
D07495 		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 97, 98
16Behavioral: six-foods elimination diet----[1] 98
17Benralizumab[1] Benralizumab[1] D09874 [1] IL5RA 💬[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬[5] 44, 45, 98, 162, 299
18Bethanechol[1] Bethanechol[1] D01000 [5] CHRM1,
CHRM2,
CHRM3,
CHRM4,
CHRM5 💬		[13] Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬[1] 98
19BT----[4] 6, 96, 97, 98
20BT-11 1000mg----[3] 96, 97, 98
21BT-11 500mg----[1] 98
22BUDESONIDE[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[9] 66, 93, 94, 95, 96, 97, 98, 228, 299
23Budesonide 0.5 mg compresse orodispersibili[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
24Budesonide 0.5 mg orodispersible tablets[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
25Budesonide 0.5mg orodispersible tablet twice daily[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
26Budesonide 1 mg compresse orodispersibili[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
27Budesonide 1 mg orodispersible tablets[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
28Budesonide 1 mg orodispersible tablets (BUL 1 mg)[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
29Budesonide 1mg orodispersible tablet twice daily[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
30Budesonide 2 mg orodispersible tablets (BUL 2 mg)[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
31Budesonide [0.4mg/ml] viscous suspension[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
32Budesonide oral suspension[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
33Budesonide oral suspension [0.2 mg/ml][1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
34Budesonide plus Prevacid[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
35BUET 0.5 mg----[1] 98
36BUET 1 mg----[1] 98
37BUET 1mg----[1] 98
38BUET 2mg----[1] 98
39BUL 0.5 mg----[1] 98
40BUL 1 mg----[1] 98
41BUU 0.4mg/ml----[1] 98
42CALY-002----[1] 98
43CC----[14] 13, 28, 46, 49, 51, 56, 84, 85, 96, 97, 98, 162, 202, 271
44CC-93538----[1] 98
45Cendakimab----[1] 98
46Citalopram[1] Citalopram[2] D00822 ,
D07704 		[1] SLC6A4 💬[2] Serotonergic synapse, Synaptic vesicle cycle 💬[7] 6, 8, 13, 18, 46, 98, 127
47Compressa effervescente 0,5 mg di budesonide per uso orodispersibile[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
48Compressa effervescente 1 mg di budesonide per uso orodispersibile[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
49Cortisol[1] Hydrocortisone[1] D00088 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 81, 98
50Cromolyn[1] Cromoglicic acid[2] D00526 ,
D07753 		--[3] 2, 85, 98
51Dexlansoprazole[1] Dexlansoprazole[1] D08903 [2] ATP4A,
ATP4B 💬		[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬[1] 98
52Diagnostic Test: Barium Esophagram[1] Barium---[1] 98
53Diagnostic Test: Bone Mineral Density (DEXA) scan----[1] 98
54Diagnostic Test: Cortisol level[1] Hydrocortisone[1] D00088 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
55Diagnostic Test: Endoscopy while on study drug----[1] 98
56Diagnostic Test: Gastrointestinal Quality of Life index----[1] 98
57Diagnostic Test: Height measurement----[1] 98
58Diagnostic Test: High-resolution manometry----[1] 98
59Diagnostic Test: Physical Examination and Questionnaires----[1] 98
60Diagnostic Test: Retrospective evaluation of endoscopy prior to study drug----[1] 98
61Diagnostic Test: Serum biomarkers----[1] 98
62Diagnostic Test: Vitamin D Measurement[1] Vitamin D---[1] 98
63Dupilumab[1] Dupilumab[1] D10354 [1] IL4R 💬[8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[4] 51, 98, 160, 162
64Dupilumab (blinded)[1] Dupilumab[1] D10354 [1] IL4R 💬[8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 98
65Dupilumab (open-label)[1] Dupilumab[1] D10354 [1] IL4R 💬[8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[1] 98
66Dupixent[1] Dupilumab[1] D10354 [1] IL4R 💬[8] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬[3] 98, 160, 162
67E0E food introduction-2nd----[1] 98
68EoE food introduction-1st----[1] 98
69EoE Food introduction-3rd dose----[1] 98
70ESO-101----[1] 98
71Esomeprazole[1] Esomeprazole[4] D01984 ,
D04056 ,
D07917 ,
D09339 		[2] ATP4A,
ATP4B 💬		[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬[8] 13, 46, 86, 98, 107, 113, 298, 299
72EsophaCap----[1] 98
73Esophageal dilation----[1] 98
74Esophagogastroduodenoscopy----[1] 98
75Etrasimod[1] Etrasimod[1] D10930 [5] S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		[3] FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬[3] 96, 97, 98
76Etrasimod L-arginine[2] Arginine,
Etrasimod		[2] D02982 ,
D10930 		[5] S1PR1,
S1PR2,
S1PR3,
S1PR4,
S1PR5 💬		[3] FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬[3] 96, 97, 98
77EUR-1100----[1] 98
78Famotidine[1] Famotidine[1] D00318 [1] HRH2 💬[3] Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬[6] 6, 46, 86, 98, 107, 300
79Fasenra[1] Benralizumab[1] D09874 [1] IL5RA 💬[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬[5] 44, 45, 98, 162, 299
80Florence 30 µg/mL----[1] 98
81Florence 60 µg/mL----[1] 98
82Florence 90 µg/mL----[1] 98
83Flovent----[1] 98
84Fluticasone[1] Fluticasone[1] D07981 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[3] 98, 228, 299
85Fluticasone MDI[1] Fluticasone[1] D07981 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
86FLUTICASONE PROPIONATE[2] Fluticasone,
Fluticasone propionate		[2] D01708 ,
D07981 		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 98, 228
87Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)[1] Fluticasone propionate[1] D01708 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
88Fluticasone Propionate, 880 mcg twice daily (after 6FED failure)[2] Fluticasone,
Fluticasone propionate		[2] D01708 ,
D07981 		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
89Fluticasone Propionate, USP[2] Fluticasone,
Fluticasone propionate		[2] D01708 ,
D07981 		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
90Gold[1] Gold---[43] 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 171, 193, 218, 222, 224, 227, 230, 235, 271, 291, 294, 296, 298, 299, 310, 318
91High dose budesonide suspension[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
92High dose budesonide tablet[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
93Honey[1] Honey[1] D06776 --[3] 57, 98, 299
94Infliximab[1] Infliximab[1] D02598 [1] TNF 💬[67] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬[26] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
95Inhaled/swallowed budesonide[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
96Intraluminal Impedance----[1] 98
97Intubated with Propofol (IP)[1] Propofol[1] D00549 [16] GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬[1] 98
98Intubated with Sevoflurane (IS)[1] Sevoflurane[1] D00547 --[1] 98
99IRL201104----[1] 98
100Jorveza[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
101Jorveza 0.5 mg compresse orodispersibili[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
102Jorveza 0.5 mg orodispersible tablets[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
103Jorveza 1 mg compresse orodispersibili[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
104Jorveza 1 mg orodispersible tablets[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
105Lansoprazole[1] Lansoprazole[1] D00355 [2] ATP4A,
ATP4B 💬		[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬[7] 63, 71, 85, 98, 166, 222, 299
106Lirentelimab[1] Lirentelimab[1] D11906 [1] SIGLEC8 💬-[1] 98
107Lirentelimab (AK002)[1] Lirentelimab[1] D11906 [1] SIGLEC8 💬-[1] 98
108Loratadine[1] Loratadine[1] D00364 [1] HRH1 💬[3] Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬[4] 13, 46, 89, 98
109Losartan[1] Losartan[2] D00357 ,
D08146 		[1] AGTR1 💬[16] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[18] 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
110LOSARTAN POTASSIUM[2] Losartan,
Potassium		[3] D00357 ,
D08146 ,
D08403 		[1] AGTR1 💬[16] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[5] 36, 98, 167, 179, 215
111Low dose budesonide tablet[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
112MEDI-563----[5] 44, 45, 98, 162, 299
113MEPOLIZUMAB[1] Mepolizumab[1] D04923 [1] IL5 💬[13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[4] 44, 45, 98, 162
114Mepolizumab 100 mg[1] Mepolizumab[1] D04923 [1] IL5 💬[13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[1] 98
115Mepolizumab 300 mg[1] Mepolizumab[1] D04923 [1] IL5 💬[13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[1] 98
116Milk[1] Cow milk---[2] 98, 210
117Mometasone[1] Mometasone[3] D00690 ,
D03325 ,
D08227 		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 98, 162
118MOMETASONE FUROATE[1] Mometasone[3] D00690 ,
D03325 ,
D08227 		[1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[2] 98, 162
119MONITOR[1] Methamidophos---[20] 2, 11, 13, 19, 28, 46, 49, 58, 65, 70, 81, 85, 86, 98, 113, 118, 129, 298, 299, 300
120Montelukast[1] Montelukast[2] D00529 ,
D08229 		[1] CYSLTR1 💬[2] Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬[8] 6, 13, 46, 61, 63, 85, 98, 228
121Montelukast/ Singulair[1] Montelukast[2] D00529 ,
D08229 		[1] CYSLTR1 💬[2] Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬[1] 98
122Nasonex----[1] 98
123NIOX MINO® Airway Inflammation Monitor[1] Methamidophos---[1] 98
124Nitric Oxide[1] Nitric Oxide[1] D00074 --[8] 46, 85, 86, 98, 210, 251, 294, 299
125Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy----[1] 98
126OC000459----[1] 98
127OMALIZUMAB[1] Omalizumab[1] D05251 [1] FCER1A 💬[4] Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬[7] 46, 53, 65, 98, 162, 226, 299
128Omeprazole[1] Omeprazole[4] D00455 ,
D01207 ,
D05259 ,
D05261 		[2] ATP4A,
ATP4B 💬		[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬[16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
129Omeprazole 20 MG Oral Tablet[1] Omeprazole[4] D00455 ,
D01207 ,
D05259 ,
D05261 		[2] ATP4A,
ATP4B 💬		[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬[1] 98
130Omeprazole 20mg BID[1] Omeprazole[4] D00455 ,
D01207 ,
D05259 ,
D05261 		[2] ATP4A,
ATP4B 💬		[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬[1] 98
131Oral Budesonide[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
132Oral Budesonide Suspension (MB-9)[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
133Oral Budesonide Suspension (OBS)[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
134Oral cromolyn sodium[1] Cromoglicic acid[2] D00526 ,
D07753 		--[1] 98
135Oral Viscous Budesonide[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
136Oral Viscous Budesonide (OVB)[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
137Other: 1 Food Elimination Diet----[1] 98
138Other: 1 Food Elimination Diet Therapy----[1] 98
139Other: 4 Food Elimination Diet----[1] 98
140Other: 4 Food Elimination Diet (post 1FED failure)----[1] 98
141Other: 6 Food Elimination Diet (after 1FED failure)----[1] 98
142Other: 6 Food Elimination Diet Therapy----[1] 98
143Other: Antigen (wheat base soy sauce) spray[1] Wheat[1] D06902 --[1] 98
144Other: Assessment of medication compliance----[1] 98
145Other: D-xylose[1] Xylose[1] D06346 --[1] 98
146Other: Elimination diet----[1] 98
147Other: Honey[1] Honey[1] D06776 --[1] 98
148Other: Medication Compliance Phone Call----[1] 98
149Other: Oral Nitric Oxide testing[1] Nitric Oxide[1] D00074 --[1] 98
150Other: Saline----[8] 2, 6, 46, 97, 98, 256, 274, 301
151Other: Symptom Survey----[1] 98
152Other: Xanthan Gum[1] Xanthan gum[1] D06333 --[1] 98
153Potassium[1] Potassium[1] D08403 --[12] 36, 46, 66, 67, 88, 94, 98, 115, 167, 179, 215, 235
154PROPOFOL[1] Propofol[1] D00549 [16] GABRA1,
GABRA2,
GABRA3,
GABRA4,
GABRA5,
GABRA6,
GABRB1,
GABRB2,
GABRB3,
GABRD,
GABRE,
GABRG1,
GABRG2,
GABRG3,
GABRP,
GABRQ 💬		[7] GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬[9] 6, 21, 22, 34, 46, 70, 84, 98, 296
155QAX576----[4] 51, 85, 96, 98
156Radiation: Computerized Tomography scan----[1] 98
157Radiation: Esophageal Barium Xray[1] Barium---[1] 98
158Radiation: Planar Images----[1] 98
159Radiation: Single Photon Emission Computed Tomography scans----[1] 98
160Reslizumab[1] Reslizumab[1] D08985 [1] IL5 💬[13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬[2] 44, 98
161RPC4046----[1] 98
162SB-240563----[3] 44, 45, 98
163SCH55700----[1] 98
164Sevoflurane[1] Sevoflurane[1] D00547 --[7] 6, 21, 22, 34, 98, 225, 296
165Sirolimus[1] Sirolimus[1] D00753 [1] MTOR 💬[51] AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬[36] 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 89, 98, 127, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331
166Steroid and Proton Pump Inhibitor Therapy----[1] 98
167Sucralfate[1] Sucralfate[1] D00446 --[1] 98
168Swallowed fluticasone[1] Fluticasone[1] D07981 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
169Technetium Tc 99m[1] Technetium Tc-99m---[2] 46, 98
170Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms[1] Lansoprazole[1] D00355 [2] ATP4A,
ATP4B 💬		[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬[1] 98
171Viaskin Milk 500 mcg[1] Cow milk---[1] 98
172Viscous/swallowed budesonide[1] Budesonide[1] D00246 [1] NR3C1 💬[1] Neuroactive ligand-receptor interaction 💬[1] 98
173Vitamin D[1] Vitamin D---[24] 3, 13, 15, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 98, 179, 222, 228, 235, 256, 274, 298, 299
174Vonoprazan[1] Vonoprazan[1] D11784 [2] ATP4A,
ATP4B 💬		[4] Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬[2] 63, 98
175Wheat[1] Wheat[1] D06902 --[3] 6, 98, 266
176Xanthan gum[1] Xanthan gum[1] D06333 --[1] 98
177Xylose[1] Xylose[1] D06346 --[1] 98
178Zofran - no intubation----[1] 98